| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| 药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
Dermal adsorption of (+)trans- and (+)cis-phenothrin into body of male rats from dust or emulsifiable concentrate (EC) was estimated to be 3-7% and 8-17%. The rate of absorption was 4-5 times faster with EC than with dust and T/2 in blood was 2-3 times longer. (14)C-phenothrin labeled at the hydroxymethyl group of the alcohol moiety was orally admin at ... 200 mg/kg to male Sprague-Dawley rats. Absorption and elimination was rapid. About 60% of radioactivity was eliminated in urine and 40% in feces in 3 days. In addn to phenothrin, 3-phenoxybenzyl alcohol and 3-phenoxybenzoic acid were found in brain, liver, kidney, and blood. Unidentified water and ether solubles were also present. Dermal adsorption of (+)trans- and (+)cis-phenothrin into body of male rats from dust or emulsifiable concentrate (EC) was estimated to be 3-7% and 8-17%. Rate of absorption was 4-5 times faster with EC than with dust. Amount absorbed through skin was almost completely excreted into urine and feces within 6 days. When admin once orally, at rate of 2 mg/kg (either isomer), about 96% of dose was recovered in excreta during following 6 days. A larger amt of (+)cis-isomer was excreted in feces than (+)trans-isomer and a larger amt of (+)trans-isomer was excreted in urine than (+)-cis-isomer. The tissue residues in rats 7 days after a single oral dose of (14)C-(1R,cis)- or (14)C-(1R,trans)-phenothrin at 10 mg/kg body weight were generally very low although the fat showed somewhat higher residue levels (1-2.5 mg/kg). Similarly, high 14C residue levels (up to 23 mg/kg) were found in the fat, 7 days after a single oral dose of the [1R,cis] isomer at 200 mg/kg body weight. For more Absorption, Distribution and Excretion (Complete) data for PHENOTHRIN (13 total), please visit the HSDB record page. Metabolism / Metabolites (14)C-Phenothrin ... was orally admin at ... 200 mg/kg to male Sprague-Dawley rats. ... Urine contained low levels of 3-phenoxybenzoic acid and its glycine conjugate and some ether and water sol material. In addn ... 3-(4'-hydroxyphenoxy)benzoic acid was present and accounted for 42.3% of radioactivity ... This cmpd was ... major metab in feces but accounted for only 11.9% of ... radioactivity. In addn to unchanged phenothrin and unidentified water and ether solubles, feces contained 3-phenoxybenzoic acid and the glycine conjugate. 3-phenoxybenzyl alcohol was not observed in urine or feces. Dermal and oral admin of (+)trans- and (+)cis-phenothrin to male rats from dust or emulsifiable concentrate produced nearly the same metabolites. Major metabolites from (+)trans-isomer were 3-phenoxybenzoic acid and its glycine conjugate and (3,4'-hydroxyphenoxy)benzoic acid and its sulfate. The cis-isomer gave larger amounts of ester metabolites. When [1R,trans]-phenothrin was given to rats at 4, 10, or 200 mg/kg body weight (oral single dose) or 4 mg/kg body weight (repetitive oral dose for 14 days), the sulfate conjugate of 4'-OH-phenoxy benzoic acid was predominant, accounting for 28, 43, 28, and 55%, respectively, of the dose. In addition, phenoxy benzoic acid (4, 10, 5, and 6%), its glycine conjugate (1,3,2, and 2%) and glucuronide (2,3,1, and 3%), and free 4'-OH-phenoxybenzoic acid (2,11,3, and 3%) were found. The sulfate conjugate of 3-(2'-hydroxyphenoxy)benzoic acid (2'-OH-PBacid) was also found as a minor metabolite. When Sprague Dawley rats were administered a single oral dose of [1R,trans]-phenothrin at 4 or 200 mg/kg body weight level or given an oral dose of 4 mg/kg body weight per day for 14 days, unmetabolized compound was found in the feces (44-45, 44-60, and 14-16% of the dose, respectively). An ester-form metabolite, the 4'-hydroxy phenoxy benzoic acid derivative of trans-phenothrin, was also detected (0.4-0.6%). For more Metabolism/Metabolites (Complete) data for PHENOTHRIN (14 total), please visit the HSDB record page. d-Phenothrin is a fast acting insecticide, effective by contact and stomach action. It is rapidly metabolized and excreted by humans and has low human toxicity. For both cis- and trans- isomers, the product was metabolized by hydrolysis, oxidation and conjugation and a large part of d-Phenothrin is excreted unchanged in the urine and the faeces. Following oral administration of the (1R)- trans - isomer, the urine is the major excretory route. The isomer is extensively metabolized to oxidative and conjugated derivatives of the hydrolysed ester. Oxidative and conjugated derivatives of the (1R)- cis -isomer are also observed but hydrolysis of the ester linkage is a minor metabolic pathway. With this isomer the faeces is the major excretory route. The metabolic profiles aree similar following dermal application, although the rates of excretion for each isomer showed some differences between the two routes of administration. The major metabolite is 3-phenoxybenzyl alcohol (PBalc). Smaller amounts of PBacid and trace amounts of 4'-OH-PBacid are also found. It is stable to storage in the dark; d-Phenothrin is relatively unstable to sunlight or ultra violet irradiation, or in alkaline media. (L866, A561) |
|---|---|
| 毒性/毒理 (Toxicokinetics/TK) |
Toxicity Summary
Both type I and type II pyrethroids exert their effect by prolonging the open phase of the sodium channel gates when a nerve cell is excited. They appear to bind to the membrane lipid phase in the immediate vicinity of the sodium channel, thus modifying the channel kinetics. This blocks the closing of the sodium gates in the nerves, and thus prolongs the return of the membrane potential to its resting state. The repetitive (sensory, motor) neuronal discharge and a prolonged negative afterpotential produces effects quite similar to those produced by DDT, leading to hyperactivity of the nervous system which can result in paralysis and/or death. Other mechanisms of action of pyrethroids include antagonism of gamma-aminobutyric acid (GABA)-mediated inhibition, modulation of nicotinic cholinergic transmission, enhancement of noradrenaline release, and actions on calcium ions. They also inhibit calium channels and Ca2+, Mg2+-ATPase. (T10, T18, L857) Toxicity Data LD50: > 5000 mg/kg (Oral, Rat) (A561) LD50: 10 000 mg/kg (Dermal, Rat) (A561) Interactions /Pyrethroid/ detoxification ... important in flies, may be delayed by the addition of synergists ... organophosphates or carbamates ... to guarantee a lethal effect. ... /Pyrethroid/ Non-Human Toxicity Values LD50 Rat oral greater than 500 mg/kg LD50 Mouse oral greater than 500 mg/kg LD50 Rat oral greater than 10000 mg/kg /(1R)-cis,trans-isomeric mixture/ LD50 Mouse oral greater than 10000 mg/kg /(1R)-cis,trans-isomeric mixture/ For more Non-Human Toxicity Values (Complete) data for PHENOTHRIN (18 total), please visit the HSDB record page. |
| 其他信息 |
Therapeutic Uses
Pyrethrins with piperonyl butoxide are used for topical treatment of pediculosis (lice infestations). Combinations of pyrethrins with piperonyl butoxide are not effective for treatment of scabies (mite infestations). Although there are no well-controlled comparative studies, many clinicians consider 1% lindane to be pediculicide of choice. However, some clinicians recommend use of pyrethrins with piperonyl butoxide, esp in infants, young children, & pregnant or lactating women ... . If used correctly, 1-3 treatments ... are usually 100% effective ... Oil based (eg, petroleum distillate) combinations ... produce the quickest results. ... For treatment of pediculosis, enough gel, shampoo, or solution ... should be applied to cover affected hair & adjacent areas ... After 10 min, hair is ... washed thoroughly ... treatment should be repeated after 7-10 days to kill any newly hatched lice. /Pyrethrins/ One hundred and one subjects with head louse infestation were entered into two separate studies, in which a phenothrin aqueous/alcoholic lotion was compared to a carbaryl lotion and a malathion lotion. Fifty subjects were treated with a single application of the phenothrin lotion, 28 with the carbaryl lotion and 23 with the malathion lotion. In the comparative study of the phenothrin and malathion lotions an inspection on the day following treatment showed no live lice remained, but that six of the subjects treated with malathion lotion still had evidence of viable eggs (p < 0.05). In one subject viable eggs were still evident at two weeks post-treatment. There were no cases, however, of live lice or viable eggs at four weeks post-treatment. Mild cutaneous side-effects were reported in five subjects, the incidence of which was not significantly different by treatment group. One subject in the phenothrin and carbaryl lotion comparative study had evidence of live lice at one week post-treatment with phenothrin lotion. This subject received no further treatment and was clear of both live lice and viable eggs at subsequent visits. A separate case of live lice infestation was found at two weeks post-treatment in a subject treated with phenothrin lotion and at four weeks post-treatment in two subjects treated with carbaryl lotion. As these subjects were free of live lice infestation at previous follow-up visits it was highly probable that these were cases of re-infestation from another source. |
| 分子式 |
C23H26O3
|
|---|---|
| 分子量 |
350.458
|
| 精确质量 |
350.188
|
| CAS号 |
26002-80-2
|
| 相关CAS号 |
D-Phenothrin;26046-85-5
|
| PubChem CID |
4767
|
| 外观&性状 |
Colorless liquid
Pale yellow to yellow-brown clear liquid |
| 密度 |
1.1±0.1 g/cm3
|
| 沸点 |
437.0±45.0 °C at 760 mmHg
|
| 闪点 |
186.6±23.3 °C
|
| 蒸汽压 |
0.0±1.0 mmHg at 25°C
|
| 折射率 |
1.588
|
| LogP |
7.47
|
| tPSA |
35.53
|
| 氢键供体(HBD)数目 |
0
|
| 氢键受体(HBA)数目 |
3
|
| 可旋转键数目(RBC) |
7
|
| 重原子数目 |
26
|
| 分子复杂度/Complexity |
512
|
| 定义原子立体中心数目 |
0
|
| SMILES |
O=C(C1C(C)(C)C1/C=C(C)\C)OCC2=CC=CC(OC3=CC=CC=C3)=C2
|
| InChi Key |
SBNFWQZLDJGRLK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H26O3/c1-16(2)13-20-21(23(20,3)4)22(24)25-15-17-9-8-12-19(14-17)26-18-10-6-5-7-11-18/h5-14,20-21H,15H2,1-4H3
|
| 化学名 |
(3-Phenoxyphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate
|
| 别名 |
KC-1001 KC 1001KC1001 Phenothrin umithrin and d-phenothrin
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ~100 mg/mL (~285.35 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: 2.5 mg/mL (7.13 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 悬浮液;超声助溶。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: 2.5 mg/mL (7.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 悬浊液; 超声助溶。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.5 mg/mL (7.13 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8534 mL | 14.2670 mL | 28.5339 mL | |
| 5 mM | 0.5707 mL | 2.8534 mL | 5.7068 mL | |
| 10 mM | 0.2853 mL | 1.4267 mL | 2.8534 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。